Literature DB >> 27660191

Bevacizumab in colorectal cancer: it should have worked.

Leonard B Saltz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27660191     DOI： 10.1016/S1470-2045(16)30213-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  Ovarian function following targeted anti-angiogenic therapy with bevacizumab.

Authors:  Atsushi Imai; Satoshi Ichigo; Kazutoshi Matsunami; Hiroshi Takagi; Ichiro Kawabata
Journal:  Mol Clin Oncol       Date:  2017-05-05

2.  The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis.

Authors:  Olivia Lauk; Karina Bruestle; Thomas Neuer; Bianca Battilana; Thi Dan Linh Nguyen; Thomas Frauenfelder; Rolf Stahel; Walter Weder; Alessandra Curioni-Fontecedro; Isabelle Opitz
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

3.  NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.

Authors:  Da Song; Jingqin Lan; Yaqi Chen; Anyi Liu; Qi Wu; Chongchong Zhao; Yongdong Feng; Jing Wang; Xuelai Luo; Zhixin Cao; Xiaonian Cao; Junbo Hu; Guihua Wang
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

Review 4.  MicroRNAs and angiogenesis: a new era for the management of colorectal cancer.

Authors:  Yufei Tang; Shaoqi Zong; Hailun Zeng; Xiaofeng Ruan; Liting Yao; Susu Han; Fenggang Hou
Journal:  Cancer Cell Int       Date:  2021-04-17       Impact factor: 5.722

Review 5.  Examining heterogeneity of stromal cells in tumor microenvironment based on pan-cancer single-cell RNA sequencing data.

Authors:  Wenhui Wang; Li Wang; Junjun She; Jun Zhu
Journal:  Cancer Biol Med       Date:  2021-08-17       Impact factor: 4.248

6.  Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models.

Authors:  Ming Qi; Shuran Fan; Maohua Huang; Jinghua Pan; Yong Li; Qun Miao; Wenyu Lyu; Xiaobo Li; Lijuan Deng; Shenghui Qiu; Tongzheng Liu; Weiqing Deng; Xiaodong Chu; Chang Jiang; Wenzhuo He; Liangping Xia; Yunlong Yang; Jian Hong; Qi Qi; Wenqian Yin; Xiangning Liu; Changzheng Shi; Minfeng Chen; Wencai Ye; Dongmei Zhang
Journal:  J Clin Invest       Date:  2022-10-03       Impact factor: 19.456

Review 7.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.